‘Groundbreaking’ Two-in-One Prostate Cancer Drug Reducing Risk of Disease Progression by Half Holds Promise for Numerous Men
- Treatment belongs to a new class of medications that accurately target tumors
- Decision on its use in the UK expected later this year
A groundbreaking treatment holds the potential to benefit numerous men with advanced prostate cancer if approved in the UK.
Clinical trials have demonstrated that a combination of enzalutamide and talazoparib, two drugs, can reduce the risk of prostate cancer progression by half.
This innovative treatment belongs to a new class of precision medications that enable more accurate targeting of tumors.
The blend of drugs received recent approval by US regulators, and a decision is expected in the UK later this year. The Lancet published results from a global trial involving over 800 men with a specific type of prostate cancer driven by genetic changes.
The findings revealed that the drug combination lowered the risk of cancer progression by 55% compared to standard treatment for these patients.
STOCK IMAGE: A treatment described as groundbreaking could benefit hundreds of men with advanced prostate cancer if approved in the UK
The study, led by Dr. Neeraj Agarwal at the Huntsman Cancer Institute in Utah, quickly gained approval from the US Food and Drug Administration.
Neli Ulrich, Chief Scientific Officer at the Huntsman Cancer Institute, stated, “This work is absolutely groundbreaking. It will make a significant difference in treatment options for many prostate cancer patients.”
Talazoparib is a PARP inhibitor, a new precision treatment for prostate cancer that blocks a protein involved in repairing cancer cells. Enzalutamide, on the other hand, is a form of hormone therapy for prostate cancer that has spread to other parts of the body.
The combination is currently under review by the UK regulator, the National Institute for Health and Care Excellence (NICE), with a decision expected in September.
If approved, it could benefit several hundred men with advanced prostate cancer each year, according to experts.
However, essential questions remain, such as whether the treatment’s current benefits in slowing cancer progression can translate into a meaningful extension of life.
Furthermore
Denial of responsibility! VigourTimes is an automatic aggregator of Global media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, and all materials to their authors. For any complaint, please reach us at – [email protected]. We will take necessary action within 24 hours.
Denial of responsibility! Vigour Times is an automatic aggregator of Global media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, and all materials to their authors. For any complaint, please reach us at – [email protected]. We will take necessary action within 24 hours.
